Article in Science immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Chenyu ZhangDivision of Immunology and Molecular Medicine, Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA 94720, USA.ORCID 0000-0002-3199-9422
Charles ChienDepartment of Electrical Engineering and Computer Sciences, University of California, Berkeley, Berkeley, CA 94720, USA.ORCID 0009-0007-7148-9375
Eglė JurgaitytėDivision of Immunology and Molecular Medicine, Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA 94720, USA.
Koharu SakiyamaDivision of Immunology and Molecular Medicine, Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA 94720, USA.ORCID 0009-0005-4613-8931
Alissa BockmanDivision of Immunology and Molecular Medicine, Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA 94720, USA.ORCID 0009-0008-5444-5036
Yeara JoDivision of Immunology and Molecular Medicine, Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA 94720, USA.ORCID 0000-0002-1340-1968
Seungwon LeeDivision of Immunology and Molecular Medicine, Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA 94720, USA.ORCID 0009-0007-8584-856X
Stephanie SilveriaDivision of Immunology and Molecular Medicine, Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA 94720, USA.ORCID 0000-0001-5278-6939
Elizabeth AndrewsDivision of Immunology and Molecular Medicine, Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA 94720, USA.ORCID 0000-0002-2265-2486
Abigail MendeDivision of Immunology and Molecular Medicine, Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA 94720, USA.ORCID 0000-0002-8893-7839
Lily ZhangDivision of Immunology and Molecular Medicine, Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA 94720, USA.
K Christopher GarciaDepartment of Molecular and Cellular Physiology and Howard Hughes Medical Institute, Stanford University School of Medicine, Palo Alto, CA 94305, USA.
Allon WagnerDivision of Immunology and Molecular Medicine, Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA 94720, USA.ORCID 0000-0001-5095-6009
Michel DuPageDivision of Immunology and Molecular Medicine, Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA 94720, USA.ORCID 0000-0002-1479-9840
David RauletDivision of Immunology and Molecular Medicine, Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA 94720, USA.ORCID 0000-0002-1257-8649
Funding
Mechanisms underlying combination therapy mobilizing NK cellsR01CA270790 · NCI · UNIVERSITY OF CALIFORNIA BERKELEY · PI DAVID H RAULET · 2022 to 2026
$2.3M
Tregulatory cell-mediated suppression of tumor elimination by NK cells and CD4 T cellsR01CA303968 · NCI · UNIVERSITY OF CALIFORNIA BERKELEY · PI Michel DuPage, DAVID H RAULET · 2025 to 2026
$1.3M
Immunosuppressive mechanisms of intratumoral regulatory T cellsR01CA292818 · NCI · UNIVERSITY OF CALIFORNIA BERKELEY · PI Michel DuPage · 2025 to 2026
Cancer cells frequently lose major histocompatibility complex class I (MHC I) to evade CD8 T cell recognition. Natural killer (NK) cells are poised to target MHC I-deficient cancer cells, but MHC I loss alone is often insufficient to unleash fully effective NK cell responses. Here, we show that selective intratumoral (IT) ablation of regulatory T cells (T
Indexed as
CD8-Positive T-LymphocytesKiller Cells, NaturalNeoplasmsT-Lymphocytes, RegulatoryAnimalsFemaleHistocompatibility Antigens Class IHumansLymphocyte ActivationMiceMice, Inbred C57BLTumor MicroenvironmentHistocompatibility Antigens Class I
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.